Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race

Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
Fintel on MSN

Century Therapeutics (IPSC) price target increased by 10.75% to 4.20

The average one-year price target for Century Therapeutics (NasdaqCM:IPSC) has been revised to $4.20 / share. This is an ...
Hosted on MSN

Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Business Wire

Induced Pluripotent Stem Cell (iPSC) Industry Trends & Forecasts 2025-2030: From Disease Modeling to Cell Therapy - iPSCs Emerge as Cornerstone of Precision Healthcare ...

DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...
technologynetworks

Scaling iPSC-Derived Cell Therapies From Innovation to Patient Care

Human induced pluripotent stem cells (iPSCs) provide a novel platform for developing cell therapies targeting diseases, from rare genetic disorders to cancer, autoimmune diseases and regenerative ...